The upper ECHELON against T-cell lymphoma

Affiliations

¹ Hematology Department, Hospices Civils de Lyon, Lyon; Lymphoma Immuno-Biology (LIB) Team, Université Claude Bernard Lyon 1, Lyon, France. Electronic address: emmanuel.bachy@chu-lyon.fr.
² Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

Free article

Editorial

E Bachy et al. Ann Oncol. 2022 Mar.

Free article

. 2022 Mar;33(3):239-241.

doi: 10.1016/j.annonc.2021.12.011. Epub 2022 Jan 10.

¹ Hematology Department, Hospices Civils de Lyon, Lyon; Lymphoma Immuno-Biology (LIB) Team, Université Claude Bernard Lyon 1, Lyon, France. Electronic address: emmanuel.bachy@chu-lyon.fr.
² Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

No abstract available

Conflict of interest statement

Disclosure GS and EB received honoraria from Takeda for advisory board participation.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.